Solara Active Pharma Q3 FY26 Net Loss at Rs 17.43 Cr
SOLARA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 11.5 pts less than Nifty Microcap 250 and 11.7 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Solara Active Pharma Q3 FY26 revenue at Rs 349 Cr, up 16% YoY. But company swung to net loss of Rs 17.43 Cr in Q3 and Rs 17.01 Cr for 9M FY26 (vs Rs 8.09 Cr profit YoY). Includes Rs 6.75 Cr exceptional charge for gratuity under new labour codes. 9M revenue down 3% to Rs 982 Cr. Going concern note flags accumulated losses of Rs 329.64 Cr and current liabilities exceeding assets by Rs 92.44 Cr. Plans Rs 134.99 Cr rights issue final call.
Negative: net loss, going concern flag, accumulated losses of Rs 329.64 Cr. Watch rights issue final call.